Sugi Predict

Sugi Predict / Compounds / SCHEMBL6478476

SCHEMBL6478476

SCHEMBL6478476

Nc1c([N+](=O)[O-])ccc2c1CCCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.44
▸ HTR2C P28335 2/20 0.44
▸ HTR2B P41595 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ TDP1 Q9NUW8 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ MAPT P10636 6/20 0.39
▸ ACHE P22303 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ NOS3 P29474 1/20 0.38
▸ NOS1 P29475 1/20 0.38
▸ NOS2 P35228 1/20 0.38
▸ PNMT P11086 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ MEN1 O00255 4/20 0.37
▸ KMT2A Q03164 4/20 0.37
▸ GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11332994 0.81 PNMT (0.50) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL29720579 0.80 HTR2A (0.45) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL9452596 0.80 HTR2A (0.45) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL9452622 0.76 MAPT (0.47) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL30503607 0.76 MAPT (0.47) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL13091607 0.75 TSHR (0.47) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL7540202 0.75 TDP1 (0.39) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL9085121 0.75 GPR35 (0.47) HTR2AHTR2CHTR2BALDH1A1CYP3A4
SCHEMBL2245003 0.75 GRIN2D (0.41) ALDH1A1CYP3A4ALOX15TDP1TSHR
SCHEMBL11342850 0.75 BAZ2B (0.43) HTR2AHTR2CHTR2BALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410161-B2 Tetrahydrobenzo-quinoline sulfonamides derivative compounds UCB Biopharma SRL (BE) 2025-09-09 — — US disclosed
US-20230051300-A1 TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS UCB Biopharma SRL (BE) 2023-02-16 — — US disclosed
US-20230051300-A1 TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS UCB Biopharma SRL (BE) 2023-02-16 — — US disclosed
CN-114845777-A Tetrahydrobenzo-quinoline sulfonamide derivative compounds UCB生物制药有限责任公司 2022-08-02 — — CN disclosed
WO-2021130262-A1 TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS UCB Biopharma SRL (BE) 2021-07-01 — — WO disclosed
US-6960608-B2 Intraocular pressure ALCON, INC. (CH) 2005-11-01 — — US disclosed
EP-1392658-A4 NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA ALCON INC (CH) 2004-10-13 — — EP disclosed
US-20040106597-A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma NOVARTIS AG (CH) 2004-06-03 — — US disclosed
EP-1392658-A1 NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA Alcon, Inc. (CH) 2004-03-03 — — EP disclosed
US-20040029937-A1 Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents NEUROSEARCH A/S. 2004-02-12 — — US disclosed
US-6624186-B2 Modulators of SKCa, IKCa and BKCa channels. NEUROSEARCH A/S (DK) 2003-09-23 — — US disclosed
WO-2002098860-A1 NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA ALCON, INC. (CH) 2002-12-12 — — WO disclosed
US-20020055526-A1 Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents NEUROSEARCH A/S (DK) 2002-05-09 — — US disclosed
EP-1144387-A1 NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-17 — — EP disclosed
WO-2000034248-A1 NEW BENZIMIDAZOLONE-, BENZOXAZOLONE-, OR BENZOTHIAZOLONE DERIVATIVES AS ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-15 — — WO disclosed
EP-0374534-B1 Quinoxaline compounds and their preparation and use NOVO NORDISK AS (DK) 1994-07-06 — — EP disclosed
US-5308845-A Pyridoquinoxalines as neuroleptic agents or treatment of hyperactivity NOVO NORDISK A/S (DK) 1994-05-03 — — US disclosed
US-5153195-A 6-ethoxyalylaminosulfonyl-7,8,9,10-tetrahydro-4-hydroxy benzoquinoxaline-2,3(1H,4H)-dione and 6-acetyl-7,8,9,10-tetrahydro-4-hydroxybenzoquinoxaline-2,3(1H,5H)-dione; neuroleptic agents NOVO NORDISK A/S (DK) 1992-10-06 — — US disclosed
US-5081123-A Quisqualate antagonists, neuroleptics NOVO NORDISK A/S (DK) 1992-01-14 — — US disclosed
EP-0374534-A1 Quinoxaline compounds and their preparation and use NOVO NORDISK A/S (DK) 1990-06-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230051300-A1 TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS HRH4, FCER2, HRH2 HTR2A 785/4885HTR2C 528/4885HTR2B 291/4885
US-20040029937-A1 Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents KCNJ2, KCNJ1, KCNJ11 HTR2A 2131/4885HTR2C 2650/4885HTR2B 2397/4885
US-12410161-B2 Tetrahydrobenzo-quinoline sulfonamides derivative compounds HRH4, FCER2, HRH2 HTR2A 785/4885HTR2C 528/4885HTR2B 291/4885
US-20040106597-A1 Novel fused indazoles and indoles and their use for the treatment of glaucoma IDO1, IDO2, GLI1 HTR2A 947/4885HTR2C 958/4885HTR2B 1247/4885
US-20020055526-A1 Benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents KCNJ2, KCNJ1, KCNJ11 HTR2A 2131/4885HTR2C 2650/4885HTR2B 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.